VOSEVI (sofosbuvir, velpatasvir, and voxilaprevir) tablets
VOSEVI is a brand-name prescription drug that’s FDA-approved to treat hepatitis C virus (HCV) infection without cirrhosis. Brand Name: VOSEVI (sofosbuvir, velpatasvir, and voxilaprevir) tablets, for oral use Initial U.S. Approval: 2017
Home | (sofosbuvir, velpatasvir, and voxilaprevir) tablets
Submit a request to access drug used to treat, diagnose or prevent serious or life-threatening conditions.We’ll get back to you within 1 business days!
For Indian Patient inquires under NPP.
Call / WhatsApp Number
+91 9289711088 (Ms. Laxmi Singh)
For any urgent inquiries or assistance needed, please reach out to our Support Team. Rest assured, we will respond within 24 hours, from Monday to Saturday, during the hours of 9:00 A.M to 18:00 PM.
VOSEVI (sofosbuvir, velpatasvir, and voxilaprevir) tablets
Sofosbuvir/velpatasvir/voxilaprevir is indicated for the treatment of hepatitis C virus (HCV) infection without cirrhosis.
VOSEVI is a prescription medicine used to treat adults with chronic (lasting a long time) hepatitis C virus (HCV) infection without cirrhosis or with compensated cirrhosis who have:
• genotype 1, 2, 3, 4, 5, or 6 infection and have previously been treated with an HCV regimen containing an NS5A inhibitor.
• genotype 1a or 3 infection and have previously been treated with an HCV regimen containing sofosbuvir without an NS5A inhibitor.
It is not known if VOSEVI is safe and effective in children.
Sofosbuvir/velpatasvir/voxilaprevir, sold under the brand name Vosevi, is a fixed-dose combination medication for the treatment of hepatitis C. It combines three drugs that each act by a different mechanism of action against the hepatitis C virus: sofosbuvir, velpatasvir, and voxilaprevir.[1]Vosevi was approved for medical use in the United States and in the European Union in July 2017. Active ingredients: sofosbuvir, velpatasvir, and voxilaprevir. Inactive ingredients: colloidal silicon dioxide, copovidone, croscarmellose sodium, lactose monohydrate, magnesium stearate, and microcrystalline cellulose.
Drug (Brand / Generic): VOSEVI / sofosbuvir, velpatasvir, and voxilaprevir
Current Indications: hepatitis C virus (HCV) infection
Marketed by:: Novartis Gilead Sciences, Inc.
Approval Date: 2017
Available as (Form & Strength): Tablets: 400 mg sofosbuvir, 100 mg velpatasvir, and 100 mg voxilaprevir
For more highlights of prescribing information regarding Indications and usage, dosage and administration, dosage forms and strengths, patient counseling information and medication guide. Click Here
Alleviare Life Sciences
About Us
Alleviare Life Sciences Pvt. Ltd. (India) serves as a facilitator for medical and pharmaceutical products, commencing its operations in 2005. Headquartered in Delhi, India, Alleviare operates nationwide, providing a range of comprehensive services to patients, doctors, hospitals, and government healthcare facilities.
Our specialization lies in facilitating access to medicines, leveraging our expertise in sourcing and providing documentation assistance for programs such as Named Patient Program, Managed Access Program, and Early Access Program. We take pride in ensuring smooth and efficient access to medications for those who require them.
Alleviare India is certified pharmaceutical facilitator / supplier /importer based in india. They are also who GDP certified. One of the pharmaceutical products they offer is “VOSEVI (sofosbuvir, velpatasvir, and voxilaprevir) tablets”.
Confirmation of the order for VOSEVI (sofosbuvir, velpatasvir, and voxilaprevir) tablets will be subject to the submission of a valid doctor’s prescription and, if applicable, an import permit.
We have delivered medicines to following cities in India – Ahmedabad, Aizawal, Aurangabad, Barshi, Bengaluru, Bhopal, Cachar, Chennai, Dibrugarh, Hyderabad, Karungapally, Kohima, Kollam, Kolkata, Mumbai, Meghalaya, Mizoram, Sikkim, Nagpur, New Delhi, Pondichery, Pune, Punjab, Thirunananthapuram, Tripura, Wardha
ALS serves as a facilitator, supplier & exporter in India assisting patients, doctors, and hospitals in importing the prescription medicine brand VOSEVI (sofosbuvir, velpatasvir, and voxilaprevir) tablets. The import process requires a valid prescription and an Import License in the Patient’s Name.
For patients from following foreign countries seeking access to AVOSEVI (sofosbuvir, velpatasvir, and voxilaprevir) tablets, they can inquire and find further information by sending their inquiries to ALS.
We have delivered medicines to following countries – Argentina, Australia, Austria, Azerbaijan, Bahrain, Brazil, Bulgaria, Cambodia, Canada, Chile, Colombia, Costa Rica, Croatia, Cyprus, Denmark, Dominican Republic, Estonia, Finland, France, Georgia, Germany, Ghana, Greece, Guatemala, India, Iraq, Ireland, Israel, Italy, Jamaica, Japan, Jordan, Kenya, Kuwait, Latvia, Lebanon, Libya, Lithuania, Malawi, Mexico, Montenegro, Nepal, Netherlands, New Zealand, Nigeria, Norway, Oman, Pakistan, Paraguay, Peru, Poland, Qatar, Romania, Saudi Arabia, Serbia, Singapore, Slovenia, Spain, Sri Lanka, Sweden, Switzerland, United Arab Emirates, United Kingdom, United States, Venezuela, Zimbabwe.
Kindly reach out to us for VOSEVI (sofosbuvir, velpatasvir, and voxilaprevir) tablets price and availability confirmation.
The price of the medicines is the cost set by the manufacturer. In addition, Named Patient support fee, shipping costs and any local tax (if applicable) will apply.
